Biotechnology company developing gene-based therapeutics for degenerative retinal diseases
Biotechnology company developing gene-based therapeutics for degenerative retinal diseases. Its lead candidate, VGX-0111, uses the ELOVL2 gene to restore retinal levels of long-chain and very-long-chain polyunsaturated fatty acids, with the goal of slowing or halting vision loss from dry age-related macular degeneration.